PCOS Has Been Renamed PMOS — And It Changes Everything for Women with ADHD
The science behind the new name isn’t just a rebrand. It’s an admission that this condition was always about the brain as much as the body, and that has profound implications for women living with ADHD.
You may have heard that PCOS got a new name this week. But buried in the science behind that name change is something nobody in the ADHD world has been talking about; a confirmation that these two conditions share the same underlying biological machinery.
On 12 May 2026, a landmark paper published in The Lancet formally renamed Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). The result of an 11-year, globally collaborative process involving over 22,000 patients and professionals across 195 countries, this wasn’t a casual rebrand. It was a scientific correction, and one that carries enormous implications for women with ADHD.
At Harley Street ADHD, a CQC-registered neurodevelopmental assessment clinic, we see the consequences of missed diagnoses every day. This new research gives us a sharper lens through which to understand why so many women with ADHD go undiagnosed for decades and why a hormonal condition that 1 in 8 women live with might be part of the picture.
Why the name changed
What’s in a name? More than you’d think.
The old name, Polycystic Ovary Syndrome, was, by scientific consensus, actively misleading. It implied the defining feature was cysts on the ovaries. In reality, many women with PCOS never had cysts at all. What they did have was a complex, multi-system hormonal disorder involving insulin, androgens, and, critically, the neuroendocrine system.
The new name corrects this. Polyendocrine Metabolic Ovarian Syndrome breaks down as:
Polyendocrine: Multiple hormone systems are disrupted, not just ovarian ones. Insulin, androgens, and neuroendocrine signalling pathways are all involved. This is where the ADHD connection lives.
Metabolic: Insulin resistance sits at the core of PMOS, with knock-on effects for cardiovascular health, weight, energy, and brain chemistry, all of which also affect ADHD.
Ovarian: The reproductive dimension remains, but is now positioned as one component of a larger, multi-system picture rather than the defining feature.
The new consensus formally recognises PMOS as involving “disturbances in insulin signalling, androgen production, neuroendocrine pathways, and ovarian function”, with psychological and neurological manifestations explicitly included as defining features of the condition
1 in 80 women worldwide have PMOS.
70% of those with PMOS remain undiagnosed.
43% higher ADHD risk in children born to mothers with PMOS.
11 years of consensus work to reach this name change.
The ADHD connection
What the new name reveals about ADHD in women.
Here is the piece that nobody is talking about in ADHD circles yet: the biology that drove the rename of PCOS is the same biology that underpins why ADHD presents so differently, and so invisibly, in women.
PMOS is now officially classified as a neuroendocrine disorder. The “polyendocrine” prefix acknowledges that the hypothalamic-pituitary axis, the brain’s hormonal command centre, is dysfunctional in women with this condition. That same axis governs dopamine regulation. And dopamine is the neurotransmitter at the heart of ADHD.
The shared biological pathway
Both ADHD and PMOS disrupt the same neurotransmitter systems. Women with PMOS have been found to have lower levels of serotonin and dysregulated dopamine, the exact deficit that drives inattention, impulsivity, and executive dysfunction in ADHD. These aren’t parallel problems running on separate tracks; they are interconnected expressions of the same underlying neuroendocrine disruption.
Androgens and insulin, the two hormones now formally placed at the centre of PMOS are directly involved in the brain’s systems for attention, impulse control, and emotional regulation. When those hormones are dysregulated, as they are in PMOS, the brain’s capacity for focus and self-regulation is compromised in ways that look, feel, and function remarkably like ADHD.
Oestrogen, dopamine, and the ADHD cycle women know too well
Many women with ADHD describe a maddening variability in their symptoms, weeks where focus feels possible, and weeks where everything collapses. This isn’t inconsistency or weakness. It is oestrogen.
Oestrogen directly modulates dopamine transmission. When oestrogen is high, dopamine signalling strengthens, and ADHD symptoms ease. When oestrogen drops, dopamine falters, and ADHD surges. For women with PMOS, oestrogen levels fluctuate more dramatically and unpredictably than in women without the condition, creating a cyclical worsening of ADHD symptoms that can be mistaken for mood disorder, burnout, or simply “having a bad week.”
This is why so many women with undiagnosed ADHD spend years being treated for anxiety or depression instead, the hormonal layer of their ADHD is invisible to clinicians who aren’t looking for it.
Insulin resistance: the hidden cognitive disruptor
The “metabolic” in PMOS is equally important for understanding ADHD in women. Insulin resistance, now formally recognised as a core feature of PMOS, affects the brain directly. Blood sugar crashes alter serotonin and dopamine production, causing the fatigue, brain fog, and inability to focus that women with both PMOS and ADHD describe with striking consistency.
For women managing ADHD, insulin dysregulation creates a biological headwind. ADHD-related behaviours: irregular meals, poor sleep, impulsive eating patterns, can in turn worsen insulin resistance, potentially triggering or exacerbating PMOS in a bidirectional cycle that neither a psychiatrist nor a gynaecologist has traditionally been trained to see as a single, connected picture.
A meta-analysis of over 1.3 million participants found that children born to mothers with PMOS were 43% more likely to develop ADHD, suggesting shared genetic and intrauterine hormonal mechanisms that may predispose both mother and child to neurodevelopmental differences.
The diagnostic gap and how PMOS helps explain it
ADHD in women is chronically underdiagnosed. Women reach their thirties, forties, and beyond before anyone connects the dots between their relentless internal chaos, their hormonal fluctuations, their exhaustion, and their identity. The PMOS renaming helps us understand why this diagnostic gap exists and why it has been so hard to close.
For decades, both PCOS and ADHD in women were described in terms of their most visible, male-pattern symptoms. PCOS was defined by cysts (often absent in women who had it). ADHD was defined by hyperactivity (rarely the presentation in women). Both conditions’ more nuanced, internalised, and cyclical presentations in women were systematically overlooked.
The PMOS rename is, at its core, an acknowledgement that the medical system built its diagnostic frameworks around incomplete data. The same is true of ADHD. And when two underdiagnosed conditions share overlapping biology, the gap between a woman’s lived experience and her diagnosis can stretch across an entire lifetime.
What this means for women seeking answers today
If you are a woman who has been told you have PCOS (or PMOS), or if you are living with symptoms that have never quite been explained; hormonal swings that derail your focus, cycles that alter your mood and concentration, a brain that works brilliantly one week and falls apart the next, this new science is relevant to you.
It means your experience is not imagined. It means the connection between your hormones and your attention is real and recognised. And it means that a comprehensive neurodevelopmental assessment, one that takes your full hormonal picture into account, is not just reasonable to seek. It is essential.
What this means for ADHD care going forward
The PMOS rename is the beginning of a longer reckoning. The Lancet paper calls for a three-year global implementation plan covering clinical guidelines in 195 countries, medical education updates, and a formal shift in how the condition is categorised and treated. For the first time, PMOS will be treated not as a gynaecological problem but as a complex, multi-system, neuroendocrine condition, which is exactly what the best ADHD clinicians have long argued ADHD in women also is.
What we hope to see, and what this science now supports, is an era of genuinely joined-up care for women. One where a PMOS diagnosis prompts a conversation about neurodevelopmental differences. Where hormonal fluctuations are taken seriously in ADHD monitoring. Where clinicians across psychiatry, endocrinology, and gynaecology speak a common language about the brain-body connection in women.
We are not there yet. But the naming of PMOS is a step in the right direction and for women who have spent years searching for an explanation that fits, it is a validation that the complexity they have always felt is real, recognised, and finally being named.
Wondering if ADHD has been missed?
Our specialist clinicians at Harley Street ADHD offer comprehensive, CQC-registered neurodevelopmental assessments for women at all stages of life, including those whose symptoms have cycled with their hormones for years without explanation.
